Velindre Cancer Centre implements the Raypilot system for prostate cancer treatment

Micropos Medical has entered into an agreement with Velindre Cancer Centre in Cardiff to implement the tumour-tracking Raypilot system, enabling high precision radiation therapy for prostate cancer. As part of the collaboration at the site, lead radiation oncologist Dr Nachi Palaniappan and his team will implement augmented stereotactic body radiation therapy (ASBRT), with the ultimate aim of integrating the method as part of the clinic’s standardised care for prostate cancer. Installation of the system and treatment of the first patient are planned for the first quarter of 2026.

“We have previous experience with SBRT and this collaboration allows us to take the next step towards even greater precision and enhanced patient quality of life,” said Dr Palaniappan. “The Raypilot system enables real-time tracking of prostate motion, reduces radiation exposure to healthy tissue and allows for increased tumour dosage. This results in improved treatment outcomes and fewer side effects. Additionally, the system eliminates the need for surgically implanted gold markers.” Micropos CEO Richard Forsberg added: “Within prostate cancer care, the focus is increasingly shifting toward quality of life after treatment. ASBRT demonstrates excellent clinical outcomes with fewer side effects, while enabling treatment in as little as three to five days.

“There is strong and growing evidence that modern radiation therapy delivers excellent clinical results with clear benefits for patients. Our collaboration with Velindre Cancer Centre marks an important step, and we look forward to enabling broader patient access to ASBRT as a standard treatment.”

Picture: Velindre Cancer Centre intends for the Raypilot system, which allows real-time tracking of prostate motion, to become part of the clinic’s standardised prostate cancer care.

Published on page 4 of the March 2026 issue of RAD Magazine.